Sanders Capital LLC boosted its stake in Pfizer, Inc. (NYSE:PFE) by 1.9% during the first quarter, Holdings Channel reports. The institutional investor owned 15,289,041 shares of the biopharmaceutical company’s stock after buying an additional 285,300 shares during the period. Pfizer makes up approximately 3.6% of Sanders Capital LLC’s holdings, making the stock its 13th largest position. Sanders Capital LLC’s holdings in Pfizer were worth $538,037,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Asset Planning Services Ltd. boosted its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Cable Hill Partners LLC boosted its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares in the last quarter. D Orazio & Associates Inc. boosted its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares in the last quarter. Finally, Acropolis Investment Management LLC boosted its position in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares in the last quarter. 69.94% of the stock is owned by hedge funds and other institutional investors.

Pfizer, Inc. (PFE) traded up 0.405% during trading on Tuesday, reaching $33.445. 4,466,313 shares of the company’s stock were exchanged. The stock has a market capitalization of $199.59 billion, a price-to-earnings ratio of 24.466 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38. The company’s 50 day moving average price is $33.38 and its 200-day moving average price is $33.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.64 earnings per share. On average, equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.84%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio is 94.12%.

WARNING: “Sanders Capital LLC Has $538.04 Million Stake in Pfizer, Inc. (PFE)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/sanders-capital-llc-has-538-04-million-stake-in-pfizer-inc-pfe/1491023.html.

A number of research analysts have issued reports on the stock. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 10th. Barclays PLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Wednesday, May 3rd. Sanford C. Bernstein reaffirmed a “buy” rating and issued a $37.00 target price on shares of Pfizer in a report on Wednesday, May 3rd. UBS AG reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $35.00 target price (up from $34.00) on shares of Pfizer in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $37.61.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.